Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06331832
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2024-03-26
First Post:
2024-03-19
Brief Title:
Expanded Access of Imvotamab IGM-2323 in Patients With RR NHL
Sponsor:
IGM Biosciences Inc
Organization:
IGM Biosciences Inc
Study Overview
Official Title:
Treatment Guidelines for Expanded Access of Imvotamab IGM-2323 in Patients With RelapsedRefractory Non-Hodgkin Lymphomas From IGM-2323-001
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Expanded Access of Imvotamab IGM-2323 in Patients with RelapsedRefractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-002339-44 | EUDRACT_NUMBER | None | None |